Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.13 per share a year ago, indicating a positive earnings surprise of +7.14% [1] Financial Performance - The company achieved revenues of $121.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.73% and up from $107.19 million in the same quarter last year [2] - Over the last four quarters, Adma Biologics has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have increased approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $130.7 million, and for the current fiscal year, it is $0.61 on revenues of $505.8 million [7] - The company's earnings outlook will be crucial for assessing future stock performance, especially in light of recent earnings report and management commentary [4][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]